Navigation Links
Cancer: Tumors absorb sugar for mobility
Date:7/28/2014

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness to join in an ordered set. Researchers are calling this behavior "mesenchymal," and they suspect it promotes metastasis.

At EPFL, Etienne Meylan's research team was able to demonstrate that the two observations appetite for sugar and mesenchymal behavior result from the same mechanism, at least in "non-small cell lung cancer." They also showed that the intensity of the phenomenon significantly influenced the chances of patient survival. Published in Cancer & Metabolism, this discovery opens up new potential targets for future therapies.

A useful mechanism, but put to work by cancer

Mesenchymal behavior is not in itself an anomaly. During embryonic development, some cells acquire these characteristics. In adults, a few cells retain this disposition.

"Mesenchymal behavior is a quite useful feature, but is abnormally reactivated in non-small cell lung cancer, which we studied," says Etienne Meylan.

The mesenchymal cancer cells studied by the researchers produce a protein called GLUT3. The latter serves the function of capturing glucose to activate various growth processes. This is the protein responsible for meeting the cell's need for sugar.

By artificially inducing mesenchymal behavior in cancer cells, the researchers found that the cells spontaneously produced GLUT3. This observation clearly shows that the same mechanism is at work. "This shift from one behavior to another, called epithelial-mesenchymal transition, is a highly debated issue. We have clearly established a cause and effect relationship between this transition and the glucose consumption of cancer cells," explains Mark Masin, lead author and PhD student at EPFL.

A case study confirms the results

Lung tumor cells produce widely varying amounts of GLUT3. This is because the gene is itself regulated by an element called ZEB1, and the amount of the latter is a function of many causes.

These variations in the amounts of GLUT3 seem to be a strong indicator of the aggressiveness of the tumor. By analyzing data from 450 patients with metastatic non-small cell lung cancer, researchers were able to show that the larger the quantity of GLUT3, the lower the chances of survival.

Patients were diagnosed relatively early and were followed for several years. Depending on whether they produced high or low amounts of GLUT3, their survival rates over seven years spanned almost 20%. "Our data don't permit us to conclude that the mechanism promotes metastasis, but it reinforces the assumption," says Mark Masin.

The discovery identifies a potential target for future medications. Etienne Meylan imagines, for example, a toxic molecule that could be specifically incorporated by GLUT3 to destroy the cell from within. "Protected by the blood-brain barrier, neurons that also produce GLUT3 would not be affected," says the researcher.


'/>"/>

Contact: Lionel Pousaz
lionel.pousaz@epfl.ch
41-795-597-161
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related medicine news :

1. Hormones after breast cancer: Not fuel for the fire after all?
2. Genetics of cancer: Non-coding DNA can finally be decoded
3. Technique Used in Some Hysterectomies May Help Spread Cancer: Study
4. Breast cancer: DMP is largely consistent with guidelines
5. Capturing cancer: A powerful new technique for early diagnosis
6. Cancer: The roots of evil go deep in time
7. Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm
8. Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
9. Enzalutamide in prostate cancer: Hints of added benefit
10. Vandetanib in thyroid cancer: Added benefit not proven
11. Cosmetics and Beauty Products Could Cause Cancer: New Website Explores Evidence Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: